Scarica l'app Stockscreener
5.11
4.66%
-0.25
Precedente Chiudi:
$5.36
Aprire:
$5.33
Volume 24 ore:
827.75K
Relative Volume:
0.56
Capitalizzazione di mercato:
$330.60M
Reddito:
$500
Utile/perdita netta:
$-54.44M
Rapporto P/E:
-4.3833
EPS:
-1.1658
Flusso di cassa netto:
$-49.91M
1 W Prestazione:
-1.54%
1M Prestazione:
+30.36%
6M Prestazione:
+9.77%
1 anno Prestazione:
+18.01%
Intervallo 1D:
$5.005
$5.33
Intervallo di 1 settimana:
$4.9922
$5.70
Portata 52W:
$2.90
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
5.11 | 330.60M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-31 | Iniziato | Leerink Partners | Outperform |
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan
IMRXImmuneering Corp Latest SEC Filings - Finviz
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm
IMRX Q1 2026 Earnings: Narrower Loss Drives Optimism for Clinical PipelineEarnings Revision Report - dars.gov.et
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com India
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Canada
Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading - Stock Titan
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade - Stock Titan
New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant - Stock Titan
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering Appoints Andrew Gengos as Chief Financial Officer - The Manila Times
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX begins dosing in phase III pancreatic cancer study, stock up - MSN
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - The Manila Times
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) - Minichart
According to a document submitted to the U.S. Securities and Exchange Commission, as of April 24, 2026, biotechnology company Immuneering Corp observed a median overall survival of 17.3 months in the intent-to-treat population of its 320 mg dosage gro - Bitget
[8-K] Immuneering Corp Reports Material Event - Stock Titan
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering stock maintained at Outperform by Oppenheimer on survival data - Investing.com South Africa
Immuneering reports median survival data from pancreatic trial - Investing.com
Immuneering Corporation Reports Promising 17.3 Months Median Overall Survival in First-Line Pancreatic Cancer Trial with Atebimetinib - Quiver Quantitative
Pancreatic cancer drug combo shows 17.3-month survival in trial - Stock Titan
Immuneering Corp stock (US45255L1089): IMRX trades around 5.36 USD ahead of key June data - AD HOC NEWS
ASCO preview, China policy, ADC linkers — a BioCentury podcast - BioCentury
Immuneering Corporation (IMRX) Slides 2.2% as Pressure Mounts Near Key SupportBreakout Stock Alerts - The Legal Advocate
IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentCFO Commentary Report - The Legal Advocate
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):